Flutamide
- Generic Name
- Flutamide
- Brand Names
- Eulexin
- Drug Type
- Small Molecule
- Chemical Formula
- C11H11F3N2O3
- CAS Number
- 13311-84-7
- Unique Ingredient Identifier
- 76W6J0943E
- Background
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
- Indication
For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
- Associated Conditions
- Stage B2-C metastatic Carcinoma of the Prostate, Stage D2 metastatic Carcinoma of the Prostate
- Associated Therapies
- -
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 112
- Registration Number
- NCT00170157
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 378
- Registration Number
- NCT00104741
- Locations
- 🇫🇷
Centre Hospital Regional Universitaire de Limoges, Limoges, France
🇫🇷Centre Hospitalier Universitaire Henri Mondor, Creteil, France
🇫🇷Clinique De Rochebelle, Ales, France
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00002881
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate
- First Posted Date
- 2004-06-22
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 63
- Registration Number
- NCT00006214
- Locations
- 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Wichita, Wichita, Kansas, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 180
- Registration Number
- NCT00002889
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 2028
- Registration Number
- NCT00002597
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 3
- Registration Number
- NCT00026377
- Locations
- 🇺🇸
Radiation Oncology, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸LaGrange Memorial Hospital, LaGrange, Illinois, United States
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer
- Conditions
- First Posted Date
- 2003-12-09
- Last Posted Date
- 2016-07-21
- Lead Sponsor
- St. Luke's Hospital, Ireland
- Target Recruit Count
- 276
- Registration Number
- NCT00003734
- Locations
- 🇮🇪
Cork University Hospital, Cork, Ireland
🇮🇪Letterkenny Hospital, Donnegal, Ireland
🇮🇪St. Vincent's Hospital, Dublin, Ireland
Hormone Therapy in Treating Patients With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 101
- Registration Number
- NCT00003323
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
- First Posted Date
- 2003-07-15
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT00003645
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.